Related Experiment Video

Updated: May 5, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

Future of targeted agents in metastatic colorectal cancer

Mauricio Burotto1, Marion L Hartley, John L Marshall

  • 1Medical Oncology Branch, National Cancer Institute, NIH, MD, USA.

Colorectal Cancer
|November 26, 2013
PubMed

Insights

Advances in targeted therapies are improving outcomes for metastatic colorectal cancer patients. Biomarkers are increasingly used to personalize treatment with monoclonal antibodies and novel agents, offering hope for longer survival and potential cures.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic colorectal cancer (mCRC) treatment has seen significant progress.
  • Targeted agents are crucial in the mCRC treatment arsenal.

Purpose of the Study:

  • To review the current landscape and future directions of targeted therapies for mCRC.
  • To highlight the role of predictive biomarkers in optimizing treatment selection.

Main Methods:

  • Review of approved and emerging targeted therapies for mCRC.
  • Discussion of predictive biomarkers for treatment response.
  • Exploration of novel therapeutic pathways.

Main Results:

  • Approved monoclonal antibodies (bevacizumab, cetuximab, panitumumab) are standard care.
  • Predictive biomarkers are emerging to guide the use of these agents.
  • Novel agents (aflibercept, regorafenib) show promise.
  • Agents targeting mTOR and TNF pathways show early evidence of benefit.

Conclusions:

  • Personalized medicine is advancing for mCRC through targeted therapies and biomarkers.
  • New therapeutic agents and pathways are expanding treatment options.
  • Future developments may lead to prolonged survival or cures for mCRC patients.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

9.1K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

9.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K